Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 50 от 240

Recruiting Phase 1

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Graves Disease

The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Начало: 19.12.2025 Край: 24.07.2028 Възраст: 18–55 г.

United States Merida Biosciences NCT07305818

Recruiting Phase 4

Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients

Acute Ischemic Stroke Patients

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Начало: 19.12.2025 Край: 31.12.2028 Възраст: от 70 г.

China Southwest Hospital, China NCT07294209

Recruiting Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA)

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extension period (ATEP) during which all participants will receive ARGX-119 IV up to 100 weeks (approximately 2 years).

Начало: 19.12.2025 Край: 28.05.2029 Възраст: 5–17 г.

United States argenx NCT07287982

Recruiting Phase 4

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

Osteoarthritis Hand Osteoarthritis Wrist

The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand/wrist osteoarthritis.

Начало: 19.12.2025 Край: 01.10.2027 Възраст: от 50 г.

United States Mayo Clinic NCT07217405

Recruiting Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity Obstructive Sleep Apnea

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

Начало: 19.12.2025 Край: 13.09.2028 Възраст: 18–99 г. Treatment

Australia, Brazil, Canada +8 Amgen NCT07225686

Recruiting Phase 2

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Castleman's Disease (CD) Idiopathic Multicentric Castleman's Disease

The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.

Начало: 18.12.2025 Край: 31.12.2028 Възраст: 18–80 г.

United States University of Pennsylvania NCT07085039

Recruiting Phase 3

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Hemophilia

This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \

Начало: 18.12.2025 Край: 30.12.2031 Възраст: 1–11 г.

Belgium, Brazil, Canada +7 Sanofi NCT07285460

Recruiting Phase 2/3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.

Начало: 18.12.2025 Край: 03.04.2030 Възраст: от 18 г.

Argentina, Canada, France +5 Merck Sharp & Dohme LLC NCT07266831

Recruiting

Just-in-Time Training for Youth Mentors

Mental Health Issue Depression Anxiety

This study will evaluate the usability, feasibility, and acceptability of a novel multi-level Just-In-Time Training (JITT) implementation strategy (JITT-EBP) that aims to equip mentors and mentor supervisors to implement evidence-based practices (EBPs) with fidelity using methods that are sustainable in rural communities. JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support. The study will conduct a pilot hybrid type 2 effectiveness-implementation trial to evaluate the use of JITT-EBP compared to usual training for implementing mentor-delivered Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST), an evidence-based depression prevention program. 96 adolescents (age 12-17) and their parents, 8-18 mentors (depending on amount of turnover), and 4 mentor supervisors will be enrolled in the trial.

Начало: 18.12.2025 Край: 31.05.2028 Възраст: от 12 г.

United States University of Minnesota NCT07129070

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Hidradenitis Suppurativa

The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.

Начало: 17.12.2025 Край: 30.09.2028 Възраст: 18–100 г.

Italy Novartis Pharmaceuticals NCT07543419

Recruiting

RESCUE: Discontinuation of GLP-1

Obesity

This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.

Начало: 17.12.2025 Край: 01.06.2026 Възраст: от 18 г.

United States Boston Scientific Corporation NCT07190794

Recruiting

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

Cystic Fibrosis (CF) Mucoviscidosis

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

Начало: 17.12.2025 Край: 04.04.2027 Възраст: от 18 г.

France University Hospital, Lille NCT07314229

Recruiting Phase 2

Study of DONQ52 in Active Celiac Disease

Celiac Disease

The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

Начало: 16.12.2025 Край: 15.12.2027 Възраст: 18–75 г. Treatment

Australia, United States Chugai Pharmaceutical NCT07239336

Recruiting

Study of Patient Preferences in Dialysis Treatment Choice: a Discrete Choice Experiment

End Stage Chronic Renal Failure

Background Compared to in-center dialysis, home dialysis is associated with better quality of life and lower healthcare system costs. However, barriers remain to its wider adoption. Chronic disease, particularly at an advanced stage, is a major driver of socioeconomic vulnerability. Among dialysis patients, the proportion of individuals covered by France's Universal Health Protection scheme (PUMA) is higher than in the general population. Similarly, those from the most disadvantaged social classes are overrepresented among dialysis patients compared to the overall French population. Dialysis can also lead to job loss. Financial compensation schemes may influence the choice of home dialysis. In France, patients who perform dialysis at home-either independently or with help from a trained family caregiver-are eligible for a "third-person compensatory allowance" (DTP). For some socioeconomically vulnerable patients, eligibility for DTP may influence their decision to opt for home treatment. The DTP is specific to the French healthcare system but could be considered in other countries, particularly within the European Union. Indeed, in most countries with income levels comparable to France, the additional cost of home dialysis is borne by the patient. This study aims to determine whether receiving financial compensation plays a role in choosing a dialysis modality (home-based versus in-center or assisted home dialysis). Objectives To investigate factors associated with patient preferences regarding renal replacement therapy. Methods A discrete choice experiment (DCE) was conducted comparing two options: home dialysis (PD and HHD, with DTP) versus in-center hemodialysis (no DTP). Perspectives If financial compensation influences patients' choices toward home dialysis, the DTP model could be used to address barriers to home-based treatment.

Начало: 16.12.2025 Край: 31.12.2027 Възраст: от 18 г.

France University Hospital, Caen NCT07535320

Recruiting Phase 1

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

Advanced Cancers

This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.

Начало: 16.12.2025 Край: 01.12.2028 Възраст: 18–75 г.

China Shanghai Chia Tai Tianqing Pharmaceutical Technology De NCT07260708

Recruiting Phase 1/2

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

Peanut Allergy

This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)

Начало: 16.12.2025 Край: 01.11.2028 Възраст: 14–50 г.

United States N-Fold, LLC NCT07117669

Recruiting Phase 2

Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.

Hemodialysis

Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.

Начало: 16.12.2025 Край: 31.12.2027 Възраст: от 18 г.

Canada London Health Sciences Centre Research Institute NCT07234890

Recruiting Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Major Depressive Disorder (MDD)

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Начало: 16.12.2025 Край: 01.08.2027 Възраст: 18–75 г.

Bulgaria, Czechia, Poland +2 Draig Therapeutics Ltd NCT07300969

Recruiting

Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment

Antibiotic Resistant Strain Transmission, Close-Contact

Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO

Начало: 15.12.2025 Край: 01.03.2029

France Assistance Publique - Hôpitaux de Paris NCT06262009

Recruiting

Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI/TRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life. The iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations

Начало: 15.12.2025 Край: 30.09.2027 Възраст: 30–80 г.

Egypt, Indonesia, Jordan +6 AstraZeneca NCT07069829

1 … 48 49 50 51 52 … 240